AzTrials
AzTrials

Medullary Thyroid Cancer (MTC)Phase 2NCT01856920

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

A Phase 2 study testing GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)] in people with Medullary Thyroid Cancer (MTC), run by NantCell, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA. CEA is found on the surface of some kinds of tumor cells, including thyroid cancer cells. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Medullary Thyroid Cancer (MTC)
What is being tested?
GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
Type of treatment
Vaccines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
35 participants
Where
1 siteUnited States
Study dates
26 Mar 2013to 8 May 2018
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participants must meet the following criteria for participation:
  • Diagnosis: Patients must have histologically confirmed medullary thyroid cancer by the Laboratory of Pathology or a pathology report and history consistent with medullary thyroid cancer. It is not uncommon for a secondary, minor pathologic focus of another form of thyroid cancer to be coincidentally found in 15-20% of patients with medullary thyroid cancer. In such cases, eligibility is based on the discretion of the investigator.
  • Patients must have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone, CT scan or MRI. (Patients who are surgical candidates and potentially rendered disease free with surgical resection are not eligible.)
  • Patients must have elevated calcitonin levels, greater than 8 pg/mL in females and 16 pg/mL in males
  • Patients with minimal or no disease related-symptoms (Minimal symptoms will include those that do not affect activities of daily living or pain that does not require regularly scheduled narcotics.)
  • No brain metastasis, history of seizures, encephalitis, or multiple sclerosis.
Show all 23Show fewer
  • Age greater than or equal to 18 years
  • ECOG performance status of 0-1 at study entry (Karnofsky greater than or equal to 70)
  • No systemic steroid use within 2 weeks prior to initiation of experimental therapy. Limited doses of systemic steroids to prevent IV contrast, allergic reaction or anaphylaxis (in patients who have known contrast allergies) are allowed.
  • Hematological eligibility parameters
  • Granulocyte count greater than or equal to 1,500/mm^3
  • Platelet count greater than or equal to 100,000/mm^3
  • Hemoglobin greater than or equal to 9 g/dL
  • Biochemical eligibility parameters (within 16 days of starting therapy)
  • Baseline renal function:
  • --- Serum creatinine less than or equal to 1.5 x upper limit of normal OR creatinine clearance on a 24-h urine collection of greater than or equal to 60 mL/min.
  • Hepatic function:
  • Bilirubin less than or equal to 1.5 mg/dl, in patients with Gilbert's syndrome, a total bilirubin less than or equal to 3.0 mg/dL
  • AST and ALT< 2.5 times upper limit of normal
  • No other active malignancies within the past 3 years (with the exception of nonmelanoma skin cancers, prostate cancer patients with stable biochemical recurrence/not on systemic therapy or carcinoma in situ of the bladder).
  • Willing to travel to the NIH for follow-up visits
  • Able to understand and sign informed consent.
  • Must agree to use effective birth control (such as a condom) or abstinence during and for a period of 6 months after the last vaccination therapy.

Who cannot join

  • Patients with any of the following will not be eligible for participation in this study:
  • Patients should have no evidence of immune dysfunction as listed below.
  • 1 Human immunodeficiency virus (HIV) positivity due to the potential for decreased immune response to the vaccine.
  • Active autoimmune diseases requiring treatment or a recent history of autoimmune disease requiring therapy, including, but not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active diverticulitis. This requirement is due to the potential risks of exacerbating autoimmunity. However, patients with vitiligo may be enrolled. (Patients with history of autoimmune thyroid conditions will be allowed as these patients will be on replacement medications.)
  • Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, eye drops or inhaled) steroid use. Limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent IV contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowed.
  • Pregnant or breast-feeding women, due to the unknown effects of GI-6207 on the fetus or infant.
Show all 15Show fewer
  • Serious inter-current medical illness which would interfere with the ability of the patient to carry out the treatment program.
  • Untreated brain metastases (or local treatment of brain metastases within the last 6 months) due to the poor prognosis of these patients and difficulty ascertaining the cause of neurologic toxicities.
  • Patients with pericardial masses >1 cm or thoracic lesions larger than 2 cm will be excluded.
  • Concurrent chemotherapy.
  • Chronic hepatitis infection, including B and C, because potential immune impairment caused by these disorders may diminish the effectiveness of this immunologic therapy.
  • Participation in another interventional clinical trial at the time of enrollment.
  • Any significant disease that, in the opinion of the investigator, may impair the patient's tolerance of study treatment.
  • Significant dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
  • Patients with second malignancy within 3 years of enrollment; patients treated surgically with a curative intent, such as non-melanoma skin cancers, localized kidney cancer or carcinoma in situ of the bladder, are not excluded. Patients with MEN2 and a history of pheochromocytoma will also not be excluded. In addition patients with prostate cancer who do not require systemic therapy will not be excluded. (A secondary, minor pathologic focus of another form of thyroid cancer may be coincidentally found in 15-20% of patients with medullary thyroid cancer. In such cases, eligibility is based on the discretion of the investigator.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • NIH Clinical Center

    Bethesda, Maryland, 20892

Other trials in United States

About this study

Official title: A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer

Background:

  • GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA. CEA is found on the surface of some kinds of tumor cells, including thyroid cancer cells. Researchers want to see if GI-6207 can encourage the body's immune system to attack and kill tumor cells that contain the CEA protein. They will test to see whether this vaccine is a safe and effective treatment for medullary thyroid cancer that has not responded to earlier treatments.
Read more

Objectives:

  • To test the safety and effectiveness of the GI-6207 vaccine for advanced medullary thyroid cancer.

Eligibility:

  • Individuals at least 18 years of age who have medullary thyroid cancer that has not responded to earlier treatments.

Design:

  • Participants will be screened with a physical exam and medical history. They will provide blood and tumor samples and have an imaging study of the neck and chest. They will also have a skin test to make sure that they are not allergic to the yeast in the vaccine.
  • Participants will be divided into two groups. One group will start to take GI-6207 immediately for 1 year. The second group will have 6 months of monitoring and tests with no vaccine, and then will take GI-6207 for 1 year.
  • GI-6207 will be given every other week for the first seven visits (about 3 months), and then monthly for the remaining year of treatment. It will be given as injections beneath the arm and in the upper thigh. These locations will help the vaccine enter the lymph nodes and reach the immune system more quickly.
  • Participants will be monitored with frequent blood and urine tests and imaging studies.
  • Participants will have regular follow-up visits after their year of study vaccines.
Read the detailed description

BACKGROUND:

  • CEA is overexpressed in multiple malignancies, including medullary thyroid cancer where CEA is universally expressed on tumor cells.
  • There is no standard treatment for patients with asymptomatic or minimally symptomatic, metastatic medullary thyroid cancer. The only effective FDA-approved therapy (vandetanib) comes with significant toxicity, so it is not used until patients have symptomatic or rapidly progressing disease.
  • Preclinical studies have shown that GI-6207 can induce a strong immune response to CEA as well as therapeutic anti-tumor responses.
  • A previous Phase I GI-6207 study has demonstrated safety and enhanced immune response in some patients.
  • Preliminary data suggests that tumor growth rates can be calculated in medullary thyroid cancer patients within 3 months
  • Retrospective data from prostate cancer studies suggest that vaccines can alter tumor growth rates within 3-4 months

OBJECTIVES:

Primary:

-To determine the effect of GI-6207 on calcitonin growth rate kinetics after 6 months of therapy in patients with medullary thyroid cancer

ELIGIBILITY:

  • Patients will have evidence of metastatic medullary thyroid cancer including disease that is evaluable on bone or CT scan.
  • Patients with minimal or no disease related-symptoms (minimal symptoms will include those that do not affect activities of daily living or pain that does not require regularly schedule narcotics.)
  • ECOG 0-1
  • No previous chemotherapy
  • No previous vandetanib
  • Should have no autoimmune diseases; no evidence of being immunocompromised; no serious inter-current medical illness; no cardiac disease; no prior splenectomy. (History of previous thyroid autoimmune disease will be allowed as these patients will have had total thyroidectomy.)
  • No brain metastasis, history of seizures, encephalitis, or multiple sclerosis
  • No pericardial-based masses greater than 1 cm or thoracic lesions larger than 2 cm

Design:

  • Randomized, phase 2 study to determine the effect of GI-6207 on calcitonin growth rate after 6 months of GI-6207
  • Patients will be randomized to either initial GI-6207 therapy or 6 months of surveillance followed by GI-6207 therapy.
  • GI-6207 will be administered subcutaneously at 4 sites at dose of 10 yeast units per site, biweekly for 7 visits (day 1, 15, 29, 43, 57, 71, 85), then monthly up to 1 year of treatment. (For patients randomized to surveillance and then GI-6207, they will get a full year of GI-6207 after a 6 month surveillance period.)
  • Once patients have completed one year of therapy with GI-6207, patients without radiographic progression will have the option to receive vaccine every 3 months for an additional 12 months. Patients who remain on vaccine will continue to be scanned every 3 months.
  • Immune monitoring via apheresis will be done prior to enrollment and at 6 months for all appropriate and consenting patients. Patients who are evaluable for immunologic response by the ELISPOT Assay (HLA 02, 03 and 24) will have apheresis at start of GI-6207 therapy and then every 3 months while on GI-6207 treatment when feasible.
Being tested
GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
Keywords
Calcitonin, T-cells, Immune Response, HLA Patients, Vaccine
Medical subject headings
Carcinoma, Medullary

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]Biological

    GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.

Study groups in NCT01856920
Study groupRoleWhat they receive
AExperimentalGI-6207 for 1 year
Receives: Biological: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
BExperimental6 months of surveillance followed by GI-6207 for 1 year
Receives: Biological: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Calcitonin Growth Rate

    NCI developed an equation based on the assumption that the change of a tumor's quantity during therapy results from 2 independent component processes: an exponential (first-order kinetics) decrease/regression and an exponential regrowth of the tumor. The equation is f(t) = exp(-d*t)+exp(g*t) (A) where exp is the base of the natural logarithm, and f(t) is the MTC calcitonin measurement at time t in days, divided by the tumor measurement at day 0, the time at which treatment is commenced. Rate decay constant d (days^(-1) )represents the exponential decrease of the tumor marker signal during therapy. Rate growth constant g (days-^(1) )represents the exponential growth of the tumor during treatment. For each patient an attempt to fit Equation (A) to each data set for which more than one data point is available. Linear regressions to evaluate the relationship between the growth rate constant,g, or other parameters will be implemented using the polynomial linear routine of Sigmaplot 9.0.

    Measured: after 6 months of therapy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2013 (estimated)
  2. Study start26 Mar 2013
  3. Primary completion8 May 2018
  4. Study completion8 May 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01856920
Sponsor's protocol ID
QUILT-3.006
Other IDs
13-C-0095
Status last verified
Jun 2024
First submitted
8 May 2013
Last updated
9 Jul 2024
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate. 1998 Jul 1;36(2):129-38. doi: 10.1002/(sici)1097-0045(19980701)36:23.0.co;2-d.

    PubMed 9655265

  • Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008 Nov 10;26(32):5275-83. doi: 10.1200/JCO.2008.17.8954. Epub 2008 Oct 6.

    PubMed 18838703

  • O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007 Dec 15;110(12):2614-27. doi: 10.1002/cncr.23086.

    PubMed 18000991

  • Del Rivero J, Donahue RN, Marte JL, Gramza A, Bilusic M, Cordes L, Karzai F, Schlom J, Gulley JL, Madan RA. A phase 2 study of GI-6207 in patients with recurrent medullary thyroid cancer. Oncologist. 2026 Jan 17;31(2):oyaf429. doi: 10.1093/oncolo/oyaf429.

    PubMed 41467761

  • Del Rivero J, Donahue RN, Marte JL, Gramza AW, Bilusic M, Rauckhorst M, Cordes L, Merino MJ, Dahut WL, Schlom J, Gulley JL, Madan RA. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. Front Endocrinol (Lausanne). 2020 Aug 7;11:490. doi: 10.3389/fendo.2020.00490. eCollection 2020.

    PubMed 32849281

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)] in people with Medullary Thyroid Cancer (MTC), run by NantCell, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 23 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Jul 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Calcitonin Growth Rate (time frame: after 6 months of therapy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01856920, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in